Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 12, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| February 9, 2018 | Ordinary Shares (25p each) | £12.9752 | 180 shares (aggregate) | London Stock Exchange (XLON) |
Material Changes
The filing reports no material changes to the company's financial position or operations. It details routine acquisitions of Ordinary Shares under the Company's Share Reward Plan by ten senior executives. Each transaction consisted of partnership shares and matching shares acquired at the same price.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of share transactions.
Important Facts for Investors
- Insider Activity: Ten senior executives, including the CEO (Ms E Walmsley) and CFO (Mr S Dingemans), acquired shares on February 9, 2018.
- Transaction Type: All acquisitions were made under the Company's Share Reward Plan, consisting of partnership and matching shares.
- Volume: The aggregate volume for all reported transactions was 180 Ordinary Shares.
- Price: All shares were acquired at a uniform price of £12.9752.
- Financial Data: No financial statements or performance metrics are included in this specific filing.